Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Foster

Showing results (1291-1300 of 1,472) with videos related to

Pageof 148
Sort By:
The Annals of Thoracic Surgery|April 23, 2016
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
BMJ (Clinical Research Ed.)|July 4, 2013
Care in specialist medical and mental health unit compared with standard care for older people with cognitive impairment admitted to general hospital: randomised controlled trial (NIHR TEAM trial)Sarah E Goldberg, Lucy E Bradshaw, Fiona C Kearney, et al.
Nature Communications|October 21, 2021
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failureDavid A Smith, Carlota Fernandez-Antunez, Andrea Magri, et al.
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2013
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsisWilliam Alazawi, Helen Heath, Jennifer A Waters, et al.
The Journal of Infection|October 20, 2019
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance GroupDaniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, et al.
Cancer|January 29, 2008
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
Ecology and Evolution|September 2, 2017
Phylogeography of a migratory songbird across its Canadian breeding range: Implications for conservation unitsSamuel Haché, Erin M Bayne, Marc-André Villard, et al.
Pageof 148

Showing results (1291-1300 of 1,472) with videos related to

Sort By:
Pageof 148
The Annals of Thoracic Surgery|April 23, 2016
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032)Michael S Kent, Sumithra J Mandrekar, Rodney Landreneau, et al.
BMJ (Clinical Research Ed.)|July 4, 2013
Care in specialist medical and mental health unit compared with standard care for older people with cognitive impairment admitted to general hospital: randomised controlled trial (NIHR TEAM trial)Sarah E Goldberg, Lucy E Bradshaw, Fiona C Kearney, et al.
Nature Communications|October 21, 2021
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failureDavid A Smith, Carlota Fernandez-Antunez, Andrea Magri, et al.
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2013
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsisWilliam Alazawi, Helen Heath, Jennifer A Waters, et al.
The Journal of Infection|October 20, 2019
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance GroupDaniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, et al.
Cancer|January 29, 2008
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
Ecology and Evolution|September 2, 2017
Phylogeography of a migratory songbird across its Canadian breeding range: Implications for conservation unitsSamuel Haché, Erin M Bayne, Marc-André Villard, et al.
Pageof 148